Gent, Belgium, 27 October 2020 – Today V-Bio Ventures announces its investment in Animab, a new venture spin-off from VIB, in a EUR 3.4 million Seed financing round. The company develops monoclonal antibodies for oral administration to ensure intestinal health of livestock. The initial focus is on improving the resilience of piglets during the fragile post-weaning period. The start-up will use the seed capital to develop its first oral antibody product for protection against ETEC and initiate a product portfolio for the livestock industry.
The German pharmaceutical giant Boehringer Ingelheim has acquired GST, a stem cell specialist based in Belgium. A part of the Anacura Group, GST’s main focus is in animal health, with its main product being a stem cell therapy for injured horses. Despite the acquisition, the company will remain in its labs near Ghent, keeping its research and production rooted in Flemish soil.
Ghent, Belgium, 27 July 2020 – GST, the stem cell specialist for horses and pets within the Anacura Group, has been acquired by Boehringer Ingelheim. The acquisition follows two years of successful cooperation. Research and production will continue in Anacura’s labs, close to Ghent, Belgium. The current management and staff will play a crucial role in the implementation and further development of stem cell technology within Boehringer Ingelheim.
Animals have been used throughout history to understand human physiology and to resolve scientific questions related to health and disease. Nowadays, however, both scientists and the public are pushing for better options to animal testing, and so increasing efforts are being put into developing and promoting these alternative methods. Two such initiatives are being spearheaded by the Vrije Universiteit Brussel (VUB): The Innovation Centre for 3R Alternatives (IC-3Rs) and the RE-Place project.
Gent, Belgium, 27 October 2020 – Today V-Bio Ventures announces its investment in Animab, a new venture spin-off from VIB, in a EUR 3.4 million Seed financing round. The company develops monoclonal antibodies for oral administration to ensure intestinal health of livestock. The initial focus is on improving the resilience of piglets during the fragile post-weaning period. The start-up will use the seed capital to develop its first oral antibody product for protection against ETEC and initiate a product portfolio for the livestock industry.
The German pharmaceutical giant Boehringer Ingelheim has acquired GST, a stem cell specialist based in Belgium. A part of the Anacura Group, GST’s main focus is in animal health, with its main product being a stem cell therapy for injured horses. Despite the acquisition, the company will remain in its labs near Ghent, keeping its research and production rooted in Flemish soil.
Ghent, Belgium, 27 July 2020 – GST, the stem cell specialist for horses and pets within the Anacura Group, has been acquired by Boehringer Ingelheim. The acquisition follows two years of successful cooperation. Research and production will continue in Anacura’s labs, close to Ghent, Belgium. The current management and staff will play a crucial role in the implementation and further development of stem cell technology within Boehringer Ingelheim.
Animals have been used throughout history to understand human physiology and to resolve scientific questions related to health and disease. Nowadays, however, both scientists and the public are pushing for better options to animal testing, and so increasing efforts are being put into developing and promoting these alternative methods. Two such initiatives are being spearheaded by the Vrije Universiteit Brussel (VUB): The Innovation Centre for 3R Alternatives (IC-3Rs) and the RE-Place project.